Zevra Therapeutics (ZVRA) Times Interest Earned (2014 - 2026)
Zevra Therapeutics' (ZVRA) quarterly Times Interest Earned came in at $30.48 in Q1 2026, up 3413.7% YoY from $0.87 in Q1 2025, and up 391.85% on a QoQ basis from -$10.44 in Q4 2025.
Zevra Therapeutics (ZVRA) Times Interest Earned (2014 - 2026) Analysis & Trends
Zevra Therapeutics (ZVRA) has 13 years of Times Interest Earned data on file, last reported at $30.48 in Q1 2026.
- Quarterly Times Interest Earned rose 3413.7% year-over-year to $30.48 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.11 (up 90.96% YoY) and the FY2025 annual result came in at -$0.69, down 15.72% from the prior year.
- Times Interest Earned rose to $30.48 in Q1 2026, from -$10.44 in the prior quarter.
- In the past five years, Times Interest Earned ranged from a high of $30.48 in Q1 2026 to a low of -$54.78 in Q4 2022.
- A 5-year average of -$13.19 and a median of -$10.06 in 2023 frame the typical range for Times Interest Earned.
- Annual changes were most pronounced in 2023 — Times Interest Earned sank 914.93% — and 2026, when it soared 3413.7%.
- Tracing ZVRA's Times Interest Earned over 5 years: stood at -$54.78 in 2022, then jumped by 73.52% to -$14.5 in 2023, then jumped by 51.56% to -$7.03 in 2024, then plunged by 48.62% to -$10.44 in 2025, then jumped by 391.85% to $30.48 in 2026.
- The last three Times Interest Earned figures came in at $30.48 (Q1 2026), -$10.44 (Q4 2025), and $2.02 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Zevra Therapeutics | 671.75 Mn | 450.18 Mn | 38.18 Mn | 9.63 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.63 |
| Mar 31, 2026 | 30.48 |
| Dec 31, 2025 | -10.44 |
| Sep 30, 2025 | 2.02 |
| Jun 30, 2025 | -35.36 |
| Mar 31, 2025 | -0.92 |
| Dec 31, 2024 | -7.03 |
| Sep 30, 2024 | -4.20 |
| Jun 30, 2024 | -11.28 |
| Mar 31, 2024 | -3.30 |
| Dec 31, 2023 | -14.50 |
| Sep 30, 2023 | -41.98 |
| Jun 30, 2023 | -31.74 |
| Mar 31, 2023 | -9.67 |
| Dec 31, 2022 | -54.78 |
| Sep 30, 2022 | -4.14 |
| Jun 30, 2022 | -14.15 |
| Dec 31, 2021 | -11.89 |
| Sep 30, 2021 | -52.90 |
| Jun 30, 2021 | 2.82 |